Live Breaking News & Updates on Updated Long Term Results

Stay updated with breaking news from Updated long term results. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 RE

NEWARK, CA / ACCESSWIRE / May 14, 2024 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced that additional data from the rusfertide Phase 2 REVIVE open label extension study will be the focus of an oral presentation at the European Hematology Associatio. ....

Ann Arbor , United States , Hall Goya , Kristenm Pettit , Corey Davis , Division Of Hematology Oncology , Department Of Internal Medicine , Network Of Companies , University Of Michigan , European Hematology Association , Protagonist Therapeutics Inc , Protagonist Therapeutics , Presentation Title , Updated Long Term Results , Study Investigating , Hepcidin Mimetic Rusfertide , Polycythemia Vera Patients , Hematocrit Control , Therapeutic Phlebotomy , Internal Medicine , Conference Session , Abstract Details , Hepcidin Mimetic , Polycythemia Vera , Nishit Modi , Clinical Pharmacology ,

Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up ...

Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up ...
pr-inside.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pr-inside.com Daily Mail and Mail on Sunday newspapers.

United States , Ann Arbor , Hall Goya , Kristenm Pettit , Corey Davis , University Of Michigan , Virginia Amannentente Network Of Companies , Department Of Internal Medicine , Division Of Hematology Oncology , News Network , Protagonist Therapeutics Inc , European Hematology Association , Protagonist Therapeutics , Oral Presentation Title , Updated Long Term Results , Study Investigating , Hepcidin Mimetic Rusfertide , Polycythemia Vera Patients , Hematocrit Control , Therapeutic Phlebotomy , Internal Medicine , Conference Session , Abstract Details , Presentation Title , Hepcidin Mimetic , Polycythemia Vera ,

Protagonist Therapeutics, Inc.: Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress

Protagonist Therapeutics, Inc.: Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United States , Ann Arbor , Hall Goya , Kristenm Pettit , Corey Davis , Department Of Internal Medicine , Division Of Hematology Oncology , Protagonist Therapeutics Inc , University Of Michigan , European Hematology Association , Network Of Companies , Protagonist Therapeutics , Presentation Title , Updated Long Term Results , Study Investigating , Hepcidin Mimetic Rusfertide , Polycythemia Vera Patients , Hematocrit Control , Therapeutic Phlebotomy , Internal Medicine , Conference Session , Abstract Details , Hepcidin Mimetic , Polycythemia Vera , Nishit Modi , Clinical Pharmacology ,

Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress

Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress
bignewsnetwork.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bignewsnetwork.com Daily Mail and Mail on Sunday newspapers.

United States , Ann Arbor , Kristenm Pettit , Corey Davis , Hall Goya , Protagonist Therapeutics Inc , European Hematology Association , University Of Michigan , Division Of Hematology Oncology , Department Of Internal Medicine , Network Of Companies , Protagonist Therapeutics , Presentation Title , Updated Long Term Results , Study Investigating , Hepcidin Mimetic Rusfertide , Polycythemia Vera Patients , Hematocrit Control , Therapeutic Phlebotomy , Internal Medicine , Conference Session , Abstract Details , Hepcidin Mimetic , Polycythemia Vera , Nishit Modi , Clinical Pharmacology ,

Orelabrutinib Data Presented at the 63rd Annual Meeting of ASH

/PRNewswire/ InnoCare Pharma (HKEX: 09969), a leading biotech company, announced today that leading PIs presented latest data of BTK inhibitor orelabrutinib. ....

United States , Hong Kong , New Jersey , Wei Xu , Daobin Zhou , Orelabrutinib Monotherapy , Jianyong Li , Ming Hou , Waldenstrom Macroglobulinemia , Innocare Pharma , Chunhua Lu , American Society Of Hematology , China National Medical Products Administration , Drug Administration , American Society , Annual Meeting , Professor Daobin Zhou , Chronic Lymphocytic , Small Cell Leukemia , Primary Immune Thrombocytopenia , Professor Ming Hou , Refractory Waldenstrom , Refractory Chronic Lymphocytic , Small Lymphocytic Lymphoma , Updated Long Term Results , Selective Bruton ,